Julie Winstanley
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Julie Winstanley has a total of 208 co-authors. Here are the top co-authors by number of shared publications:
- Edward White
Osman Consulting Pty Ltd, Sydney, New South Wales, Australia
11 shared publications - John F. Thompson
Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia
8 shared publications - Richard Scolyer
Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia
4 shared publications Frances Boyle
3 shared publications- Bella Vivat
Marie Curie Palliative Care Research Department, Division of Psychiatry, University College London
2 shared publications Brad Smith
IMPAQ International, Philadelphia, PA, USA
2 shared publications
Latest Publications
- Open Access
- 13 November 2023
- Published by Elsevier in Measurement and Evaluations in Cancer Care
- Vol. 1
The HAIR-QoL measure Part 2: Validation of an instrument to measure of the severity and impact of chemotherapy-induced alopecia (CIA)
- 13 November 2023
- Published by Elsevier in Measurement and Evaluations in Cancer Care
- Vol. 1
Open AccessThe HAIR-QoL measure Part 2: Validation of an instrument to measure of the severity and impact of chemotherapy-induced alopecia (CIA)
- 5 March 2020
- Published by Springer Nature in Quality of Life Research
- Vol. 29 (8) , 2021-2027
Patient-reported outcomes in melanoma survivors at 1, 3 and 5 years post-diagnosis: a population-based cross-sectional study
Purpose There is a lack of population-based data describing patient reported outcomes (PROs) in melanoma survivors which could guide the development of interventions and resources. This study assessed overall quality of life (QoL), self-reported symptoms and unmet information needs in melanoma survivors 1, 3 or 5 years post-diagnosis. Methods A cross-sectional postal survey was conducted in Victoria, Australia, with eligible melanoma survivors identified from a population-based cancer registry. Patient-reported outcome measures included the EuroQoL 5-Dimension 5-Level (EQ-5D-5L), and self-reported symptoms, difficulties and information needs. Associations between demographic, disease and care-related factors and QoL were also assessed. Results A total of 476 melanoma survivors participated in the study (response rate 46.5%). Anxiety and depressive symptoms were more prevalent in survivors compared to the general population (30.7% vs 21.6%; p < 0.01). Fear of cancer recurrence (48.3%) and fear of cancer spreading (37.8%) were the most commonly reported symptom items, and approximately one in five melanoma survivors had unmet information needs related to psychological aspects of living with melanoma. Recurrent melanoma, living in a nursing home, chronic comorbidities, and melanoma diagnosed at > 2 mm thickness were associated with lower QoL. Conclusion A large proportion of melanoma survivors reported ongoing quality of life deficits, fear of cancer recurrence, as well as unmet information needs up to 5 years after diagnosis. Patients may benefit from tailored informational resources and interventions that address the psychological aspects of living with and beyond melanoma.
- 5 March 2020
- Published by Springer Nature in Quality of Life Research
- Vol. 29 (8) , 2021-2027
Patient-reported outcomes in melanoma survivors at 1, 3 and 5 years post-diagnosis: a population-based cross-sectional study
Purpose There is a lack of population-based data describing patient reported outcomes (PROs) in melanoma survivors which could guide the development of interventions and resources. This study assessed overall quality of life (QoL), self-reported symptoms and unmet information needs in melanoma survivors 1, 3 or 5 years post-diagnosis. Methods A cross-sectional postal survey was conducted in Victoria, Australia, with eligible melanoma survivors identified from a population-based cancer registry. Patient-reported outcome measures included the EuroQoL 5-Dimension 5-Level (EQ-5D-5L), and self-reported symptoms, difficulties and information needs. Associations between demographic, disease and care-related factors and QoL were also assessed. Results A total of 476 melanoma survivors participated in the study (response rate 46.5%). Anxiety and depressive symptoms were more prevalent in survivors compared to the general population (30.7% vs 21.6%; p < 0.01). Fear of cancer recurrence (48.3%) and fear of cancer spreading (37.8%) were the most commonly reported symptom items, and approximately one in five melanoma survivors had unmet information needs related to psychological aspects of living with melanoma. Recurrent melanoma, living in a nursing home, chronic comorbidities, and melanoma diagnosed at > 2 mm thickness were associated with lower QoL. Conclusion A large proportion of melanoma survivors reported ongoing quality of life deficits, fear of cancer recurrence, as well as unmet information needs up to 5 years after diagnosis. Patients may benefit from tailored informational resources and interventions that address the psychological aspects of living with and beyond melanoma.
- 25 October 2019
- Published by Wiley in Psycho-Oncology
- Vol. 29 (2) , 321-330
Development of the Melanoma Concerns Questionnaire (MCQ‐28); refinement of the EORTC QLQ‐MEL38 module
Objective Few patient‐reported outcome measures (PROMs) have been developed that adequately measure the patient‐experience following diagnosis and treatment of melanoma. Building on previous research, which developed the European Organisation for Research and Treatment of Cancer [EORTC] Quality of Life Module [QLQ‐MEL38], the aim of this study was to further test the hypothesised domain structure and psychometric properties of the Phase 3 module, in a new larger sample of melanoma patients. Methods Melanoma patients (n=270) were recruited from four countries [Australia, England, Serbia and Spain]. Patients completed the EORTC core questionnaire [QLQ‐C30], the QLQ‐MEL38 and a socio‐demographic survey. Using this new larger dataset, comparisons were made with the hypothesized domain structure of the EORTC Phase 3 module using Principal Components Analysis. Items which formed subscales in a revised domain structure were then tested for goodness of fit (GoF) to the Rasch Model. Results The original hypothesised and final domain structures were similar, but not identical. Twenty‐four items (83%) loaded onto the same distinct subscales previously generated by Phase 3 and item‐by‐item comparison of the two pattern matrices indicated an extremely close match. Ten items were removed from the QLQ‐MEL38 Phase 3 module and re‐scoring of some items was required. Four subscales, together with five individual items, comprised the final instrument. Conclusion The newly developed measure [named the Melanoma Concerns Questionnaire©; MCQ‐28©] was found to tap into several important psycho‐social domains of concern to melanoma patients, particularly those being managed in ‘usual’ clinic settings.
- 25 October 2019
- Published by Wiley in Psycho-Oncology
- Vol. 29 (2) , 321-330
Development of the Melanoma Concerns Questionnaire (MCQ‐28); refinement of the EORTC QLQ‐MEL38 module
Objective Few patient‐reported outcome measures (PROMs) have been developed that adequately measure the patient‐experience following diagnosis and treatment of melanoma. Building on previous research, which developed the European Organisation for Research and Treatment of Cancer [EORTC] Quality of Life Module [QLQ‐MEL38], the aim of this study was to further test the hypothesised domain structure and psychometric properties of the Phase 3 module, in a new larger sample of melanoma patients. Methods Melanoma patients (n=270) were recruited from four countries [Australia, England, Serbia and Spain]. Patients completed the EORTC core questionnaire [QLQ‐C30], the QLQ‐MEL38 and a socio‐demographic survey. Using this new larger dataset, comparisons were made with the hypothesized domain structure of the EORTC Phase 3 module using Principal Components Analysis. Items which formed subscales in a revised domain structure were then tested for goodness of fit (GoF) to the Rasch Model. Results The original hypothesised and final domain structures were similar, but not identical. Twenty‐four items (83%) loaded onto the same distinct subscales previously generated by Phase 3 and item‐by‐item comparison of the two pattern matrices indicated an extremely close match. Ten items were removed from the QLQ‐MEL38 Phase 3 module and re‐scoring of some items was required. Four subscales, together with five individual items, comprised the final instrument. Conclusion The newly developed measure [named the Melanoma Concerns Questionnaire©; MCQ‐28©] was found to tap into several important psycho‐social domains of concern to melanoma patients, particularly those being managed in ‘usual’ clinic settings.
- Open Access
- 21 August 2019
- Published by Wiley in European Journal of Cancer Care
- Vol. 28 (6) , e13145
Associations between sex, age and spiritual well‐being scores on the EORTC QLQ‐SWB32 for patients receiving palliative care for cancer: A further analysis of data from an international validation study
Objective The EORTC QOL Group has recently completed the cross‐cultural development and validation of a standalone measure of spiritual well‐being (SWB) for cancer patients receiving palliative care: the EORTC QLQ‐SWB32. The measure includes four scales: Relationships with Others, Relationship with Self, Relationship with Someone or Something Greater, and Existential, plus a Global‐SWB item. This paper reports on further research investigating relationships between sex, age and SWB for patients receiving palliative care for cancer—adjusting for other socio‐demographic, clinical and function variables, including WHO performance status and EORTC QLQ‐C15‐PAL emotional and physical function scores. Methods Cross‐sectional data from the validation study were used, and chi‐square, independent t tests, Mann–Whitney U tests and multiple regression analyses applied. Results The study included 451 participants with advanced and incurable cancer, from 14 countries. Adjusted analyses found better scores for female participants than males on three of the four EORTC QLQ‐SWB32 subscales; Relationship with others, Relationship with Someone or Something Greater and Existential plus Global‐SWB. Older age was positively associated with better Relationship with Self. Conclusion The findings from our participants suggest that it might be beneficial if healthcare providers seeking to address patients’ spiritual needs pay particular attention to male patients, younger patients and those with poor emotional functioning.
- 21 August 2019
- Published by Wiley in European Journal of Cancer Care
- Vol. 28 (6) , e13145
Open AccessAssociations between sex, age and spiritual well‐being scores on the EORTC QLQ‐SWB32 for patients receiving palliative care for cancer: A further analysis of data from an international validation study
Objective The EORTC QOL Group has recently completed the cross‐cultural development and validation of a standalone measure of spiritual well‐being (SWB) for cancer patients receiving palliative care: the EORTC QLQ‐SWB32. The measure includes four scales: Relationships with Others, Relationship with Self, Relationship with Someone or Something Greater, and Existential, plus a Global‐SWB item. This paper reports on further research investigating relationships between sex, age and SWB for patients receiving palliative care for cancer—adjusting for other socio‐demographic, clinical and function variables, including WHO performance status and EORTC QLQ‐C15‐PAL emotional and physical function scores. Methods Cross‐sectional data from the validation study were used, and chi‐square, independent t tests, Mann–Whitney U tests and multiple regression analyses applied. Results The study included 451 participants with advanced and incurable cancer, from 14 countries. Adjusted analyses found better scores for female participants than males on three of the four EORTC QLQ‐SWB32 subscales; Relationship with others, Relationship with Someone or Something Greater and Existential plus Global‐SWB. Older age was positively associated with better Relationship with Self. Conclusion The findings from our participants suggest that it might be beneficial if healthcare providers seeking to address patients’ spiritual needs pay particular attention to male patients, younger patients and those with poor emotional functioning.
- 22 August 2017
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 26 (2) , 483-489
Madarosis: a qualitative study to assess perceptions and experience of Australian patients with early breast cancer treated with taxane-based chemotherapy
Eyebrow and eyelash loss (madarosis) is a common and distressing side effect of chemotherapy for which no protective strategies have yet been developed. The purpose of this study was to develop an overview of perceptions and experiences of women undergoing taxane-based treatment for early breast cancer.
- 22 August 2017
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 26 (2) , 483-489
Madarosis: a qualitative study to assess perceptions and experience of Australian patients with early breast cancer treated with taxane-based chemotherapy
Eyebrow and eyelash loss (madarosis) is a common and distressing side effect of chemotherapy for which no protective strategies have yet been developed. The purpose of this study was to develop an overview of perceptions and experiences of women undergoing taxane-based treatment for early breast cancer.
- 4 August 2017
- Published by Wiley in European Journal of Cancer Care
- Vol. 26 (6) , e12697
The international phase 4 validation study of the EORTC QLQ-SWB32: A stand-alone measure of spiritual well-being for people receiving palliative care for cancer
The EORTC Quality of Life Group has just completed the final phase (field‐testing and validation) of an international project to develop a stand‐alone measure of spiritual well‐being (SWB) for palliative cancer patients. Participants (n = 451)—from 14 countries on four continents; 54% female; 188 Christian; 50 Muslim; 156 with no religion—completed a provisional 36‐item measure of SWB plus the EORTC QLQ‐C15‐PAL (PAL), then took part in a structured debriefing interview. All items showed good score distribution across response categories. We assessed scale structure using principal component analysis and Rasch analysis, and explored construct validity, and convergent/divergent validity with the PAL. Twenty‐two items in four scoring scales (Relationship with Self, Relationships with Others, Relationship with Someone or Something Greater, and Existential) explained 53% of the variance. The measure also includes a global SWB item and nine other items. Scores on the PAL global quality‐of‐life item and Emotional Functioning scale weakly‐moderately correlated with scores on the global SWB item and two of the four SWB scales. This new validated 32‐item SWB measure addresses a distinct aspect of quality‐of‐life, and is now available for use in research and clinical practice, with a role as both a measurement and an intervention tool.
- 4 August 2017
- Published by Wiley in European Journal of Cancer Care
- Vol. 26 (6) , e12697
The international phase 4 validation study of the EORTC QLQ-SWB32: A stand-alone measure of spiritual well-being for people receiving palliative care for cancer
The EORTC Quality of Life Group has just completed the final phase (field‐testing and validation) of an international project to develop a stand‐alone measure of spiritual well‐being (SWB) for palliative cancer patients. Participants (n = 451)—from 14 countries on four continents; 54% female; 188 Christian; 50 Muslim; 156 with no religion—completed a provisional 36‐item measure of SWB plus the EORTC QLQ‐C15‐PAL (PAL), then took part in a structured debriefing interview. All items showed good score distribution across response categories. We assessed scale structure using principal component analysis and Rasch analysis, and explored construct validity, and convergent/divergent validity with the PAL. Twenty‐two items in four scoring scales (Relationship with Self, Relationships with Others, Relationship with Someone or Something Greater, and Existential) explained 53% of the variance. The measure also includes a global SWB item and nine other items. Scores on the PAL global quality‐of‐life item and Emotional Functioning scale weakly‐moderately correlated with scores on the global SWB item and two of the four SWB scales. This new validated 32‐item SWB measure addresses a distinct aspect of quality‐of‐life, and is now available for use in research and clinical practice, with a role as both a measurement and an intervention tool.
- 20 March 2017
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 24 (8) , 2071-2079
Quality of Life Following Sentinel Node Biopsy for Primary Cutaneous Melanoma: Health Economic Implications
Sentinel node biopsy (SNB) is commonly performed in contemporary melanoma management, however there is a paucity of long-term quality of life (QoL) estimat
- 20 March 2017
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 24 (8) , 2071-2079
Quality of Life Following Sentinel Node Biopsy for Primary Cutaneous Melanoma: Health Economic Implications
Sentinel node biopsy (SNB) is commonly performed in contemporary melanoma management, however there is a paucity of long-term quality of life (QoL) estimat
- 25 April 2016
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 24 (9) , 3915-3924
International field testing of the psychometric properties of an EORTC quality of life module for oral health: the EORTC QLQ-OH15
Purpose This international EORTC validation study (phase IV) is aimed at testing the psychometric properties of a quality of life (QoL) module related to oral health problems in cancer patients. Methods The phase III module comprised 17 items with four hypothesized multi-item scales and three single items. In phase IV, patients with mixed cancers, in different treatment phases from 10 countries completed the EORTC QLQ-C30, the QLQ-OH module, and a debriefing interview. The hypothesized structure was tested using combinations of classical test theory and item response theory, following EORTC guidelines. Test–retest assessments and responsiveness to change analysis (RCA) were performed after 2 weeks. Results Five hundred seventy-two patients (median age 60.3, 54 % females) were analyzed. Completion took sticky saliva/mouth soreness/sensitivity to food/drink). Face and convergent validity and internal consistency were confirmed. Test–retest reliability (n = 60) was demonstrated as was RCA for patients undergoing chemotherapy (n = 117; p = 0.06). The resulting QLQ-OH15 discriminated between clinically distinct patient groups, e.g., low performance status vs. higher (p < 000.1), and head-and-neck cancer versus other cancers (p < 0.03). Conclusion The EORTC module QLQ-OH15 is a short, well-accepted assessment tool focusing on oral problems and QoL to improve clinical management. Trial Registration ClinicalTrials.gov Identifier: NCT01724333.
- 25 April 2016
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 24 (9) , 3915-3924
International field testing of the psychometric properties of an EORTC quality of life module for oral health: the EORTC QLQ-OH15
Purpose This international EORTC validation study (phase IV) is aimed at testing the psychometric properties of a quality of life (QoL) module related to oral health problems in cancer patients. Methods The phase III module comprised 17 items with four hypothesized multi-item scales and three single items. In phase IV, patients with mixed cancers, in different treatment phases from 10 countries completed the EORTC QLQ-C30, the QLQ-OH module, and a debriefing interview. The hypothesized structure was tested using combinations of classical test theory and item response theory, following EORTC guidelines. Test–retest assessments and responsiveness to change analysis (RCA) were performed after 2 weeks. Results Five hundred seventy-two patients (median age 60.3, 54 % females) were analyzed. Completion took sticky saliva/mouth soreness/sensitivity to food/drink). Face and convergent validity and internal consistency were confirmed. Test–retest reliability (n = 60) was demonstrated as was RCA for patients undergoing chemotherapy (n = 117; p = 0.06). The resulting QLQ-OH15 discriminated between clinically distinct patient groups, e.g., low performance status vs. higher (p < 000.1), and head-and-neck cancer versus other cancers (p < 0.03). Conclusion The EORTC module QLQ-OH15 is a short, well-accepted assessment tool focusing on oral problems and QoL to improve clinical management. Trial Registration ClinicalTrials.gov Identifier: NCT01724333.
- 9 April 2016
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 24 (9) , 3813-3820
Scalp cooling: a qualitative study to assess the perceptions and experiences of Australian patients with breast cancer
Purpose Chemotherapy-induced hair loss is a common and distressing side effect. Scalp cooling is increasingly being used to reduce this hair loss. The purpose of this study was to explore patients’ perceptions and experience of scalp cooling. Methods Seventeen Australian women with a diagnosis of breast cancer participated in a focus group (n = 4) or a semi-structured interview (n = 3). Both scalp-cooled and non-scalp-cooled participant views were sought. Participant perceptions and experiences of scalp cooling were discussed as part of patients’ overall chemotherapy experience and a thematic analysis conducted. Results Five themes emerged from the data: (1) scalp cooling in the context of treatment decision-making discussions, (2) hair loss expectations vs. experiences, (3) treatment-related expectations vs. experiences, (4) the promise of faster regrowth and (5) satisfaction with scalp cooling and future scalp cooling decision-making considerations. Information during treatment decision-making was the primary factor that influenced whether patient expectations were met. Faster regrowth was a motivator to continue treatment. Efficacy and tolerability of scalp cooling influenced future hypothetical treatment decision-making for both scalp-cooled and non-scalp-cooled participants. Conclusions This study provides the first in-depth exploration of patient attitudes to scalp cooling. The results highlight a need for accurate information regarding efficacy and tolerability as well as hair care information to assist patients with their treatment decision-making.
- 9 April 2016
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 24 (9) , 3813-3820
Scalp cooling: a qualitative study to assess the perceptions and experiences of Australian patients with breast cancer
Purpose Chemotherapy-induced hair loss is a common and distressing side effect. Scalp cooling is increasingly being used to reduce this hair loss. The purpose of this study was to explore patients’ perceptions and experience of scalp cooling. Methods Seventeen Australian women with a diagnosis of breast cancer participated in a focus group (n = 4) or a semi-structured interview (n = 3). Both scalp-cooled and non-scalp-cooled participant views were sought. Participant perceptions and experiences of scalp cooling were discussed as part of patients’ overall chemotherapy experience and a thematic analysis conducted. Results Five themes emerged from the data: (1) scalp cooling in the context of treatment decision-making discussions, (2) hair loss expectations vs. experiences, (3) treatment-related expectations vs. experiences, (4) the promise of faster regrowth and (5) satisfaction with scalp cooling and future scalp cooling decision-making considerations. Information during treatment decision-making was the primary factor that influenced whether patient expectations were met. Faster regrowth was a motivator to continue treatment. Efficacy and tolerability of scalp cooling influenced future hypothetical treatment decision-making for both scalp-cooled and non-scalp-cooled participants. Conclusions This study provides the first in-depth exploration of patient attitudes to scalp cooling. The results highlight a need for accurate information regarding efficacy and tolerability as well as hair care information to assist patients with their treatment decision-making.